Virginia Paton
About Virginia Paton
Virginia Paton serves as the Vice President of Clinical Science at CytomX Therapeutics, where she focuses on oncology drug development and clinical trial strategies. She has a background in pharmacy and has previously held a leadership position at BeiGene.
Work at CytomX Therapeutics
Virginia Paton serves as the Vice President of Clinical Science at CytomX Therapeutics, a position she has held since 2020. In this role, she plays a significant part in advancing clinical development strategies, focusing on innovative approaches to oncology drug development. Her work contributes to the company's mission of developing novel cancer therapies. CytomX Therapeutics is located in South San Francisco, CA, where Paton applies her extensive expertise in clinical trials to enhance the efficacy and safety of pharmaceutical products.
Previous Experience at BeiGene
Before joining CytomX Therapeutics, Virginia Paton worked at BeiGene as Executive Director from 2016 to 2020. During her tenure in Emeryville, California, she contributed to the company's initiatives in oncology drug development. Her experience at BeiGene further solidified her expertise in clinical science, particularly in the context of advancing cancer therapies.
Education and Expertise
Virginia Paton studied at The University of Texas at San Antonio, where she gained foundational knowledge in her field. She also holds a Bachelor of Science in Pharmacy from Albany College of Pharmacy of Union University. Her educational background supports her expertise in oncology drug development and clinical trials, enabling her to contribute effectively to the pharmaceutical industry.
Background in Clinical Trials
Virginia Paton possesses a strong background in clinical trials, which is essential for enhancing the efficacy and safety of pharmaceutical products. Her experience in this area has been instrumental in her roles at both CytomX Therapeutics and BeiGene. Paton's focus on clinical science underlines her commitment to advancing innovative cancer therapies through rigorous clinical development strategies.